New Antifibroblastic Medication in Dermatology: Could Nintedanib Treat Scarring?

There are a wide variety of disfiguring dermatological conditions whose pathologic substrate is represented by the unwanted deposition of collagen from dermal fibroblasts. Pirfenidone has demonstrated efficiency in the treatment of disordered collagen production when applied topically. Due to a simi...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of general medicine Vol. 15; pp. 7169 - 7172
Main Authors Cristodor, Patricia Liana, Nechifor, Alexandru, Fotea, Silvia, Nadasdy, Thomas, Bahloul, Yousef, Nicolescu, Alin Codrut, Tatu, Alin Laurentiu
Format Journal Article
LanguageEnglish
Published Macclesfield Dove Medical Press Limited 01.01.2022
Taylor & Francis Ltd
Dove
Dove Medical Press
Subjects
Alopecia
Baldness
Clinical trials
Collagen
Extracellular matrix
fibroblast
Fibroblasts
Hypothesis
Information sharing
keloid
Kinases
Lipids
Nanoparticles
nintedanib
pirfenidone
Proteins
Quantum dots
scarring
Scars
Scleroderma
Scleroderma (Disease)
Systemic scleroderma
Wound healing
Romania
Online AccessGet full text

Cover

More Information
Summary:There are a wide variety of disfiguring dermatological conditions whose pathologic substrate is represented by the unwanted deposition of collagen from dermal fibroblasts. Pirfenidone has demonstrated efficiency in the treatment of disordered collagen production when applied topically. Due to a similar mechanism of action, we also hypothesize that a similar medication, nintedanib, might have similar applications. We also propose that a liposomal technology may assist in the penetration of nintedanib and enhance its clinical effects. Keywords: nintedanib, pirfenidone, keloid, scarring, fibroblast
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S377073